Proxalutamide as a novel potent AR antagonist has been shown to downregulate the expression of ACE2 and TMPRSS2 in lung cancer cells, and also accelerate viral clearance in mild to moderate patients with COVID-19 [32]. Here, ACE2 is linked to lung carcinoma.